The Pharma Letter Podcast

ConcertAI CEO Eron Kelly on Big Tech's role in biotech

How blood cancer treatment is evolving in the Middle East

Nouscom bets on dual vaccine strategy to outsmart cancer

Is this a revolution in Alzheimer's?

Why Boehringer and GSK are betting on Ochre

ICON's AI strategy: faster, smarter trials

How real-time data could transform clinical trials

Japanese pharma in the UK

How can we use AI to program antibodies?

Breakthroughs in MASH, with 89bio CEO

How to develop cancer drugs faster, with Ellipses Pharma

CRO sector surges in bio revolution

Lilly looks to lead in Alzheimer's

AAIC preview with Eisai deputy CCO Michael Irizarry

A new way to innovate, from Flagship Pioneering

Will radical new EU regs hobble industry?

Galapagos update—with CEO Paul Stoffels

US midterms and beyond: the outlook for pharma

Focus on rare liver diseases, with Albireo CEO Ron Cooper

Inflation Reduction Act: quick take

EQRx plots radical disruption on pricing

Can AI find new drugs for metabolic diseases?

A vaccine for Alzheimer's?

Is there a data capture crisis in biotech?

Mastering the microbiome

Should US states control drug prices?

Will decentralized clinical trials become the new standard?

The rise of AI in drug discovery

Why hasn't the world embraced Sputnik V?

Better pharma supply chains

The importance of patient empowerment in multiple sclerosis care

Innovation in preleukemia

The state of biotech investing

Psychedelics in medicine

Non-opioid analgesics

Belong.Life